What is the ranking of antidepressants based on long‑term tolerability in typical adult patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Ranking Antidepressants by Long-Term Tolerability

Based on the available evidence, SSRIs as a class demonstrate superior long-term tolerability compared to other antidepressant classes, with sertraline, citalopram, escitalopram, and fluoxetine ranking highest for sustained use, while tricyclic antidepressants (TCAs) and SNRIs duloxetine and venlafaxine rank lowest due to higher discontinuation rates from adverse effects.

Evidence-Based Tolerability Hierarchy

Tier 1: Best Long-Term Tolerability

  • Sertraline - Most favorable profile across multiple studies 1
  • Citalopram - Well-tolerated with fewer dropouts 1
  • Escitalopram - Superior acceptability in head-to-head trials 1, 2
  • Fluoxetine - Associated with fewer dropouts than placebo (OR 0.88) 1
  • Agomelatine - Associated with fewer dropouts than placebo (OR 0.84) 1, 2

Tier 2: Moderate Long-Term Tolerability

  • Bupropion - Lower sexual dysfunction rates but may cause agitation 1
  • Mirtazapine - Well-tolerated but causes weight gain and sedation 1
  • Vortioxetine - Good tolerability in head-to-head studies 2

Tier 3: Lower Long-Term Tolerability

  • Paroxetine - Higher anticholinergic effects, should be avoided in older adults 1
  • Venlafaxine (SNRI) - 40% higher discontinuation risk vs SSRIs (95% CI 16-73%) 1
  • Duloxetine (SNRI) - 67% higher discontinuation risk vs SSRIs (95% CI 17-139%) 1

Tier 4: Poorest Long-Term Tolerability

  • Tricyclic Antidepressants - Number needed to harm: 4-30 for TCAs vs 20-90 for SSRIs 1
    • Amitriptyline, clomipramine, nortriptyline have highest dropout rates (OR 1.30-2.32) 2
  • Reboxetine - Least efficacious with poor tolerability 2
  • Trazodone - High dropout rates in head-to-head trials 2

Key Long-Term Tolerability Issues by Drug Class

Common persistent side effects across all antidepressants include weight gain, sexual dysfunction, sleep disturbances, fatigue, apathy, and cognitive impairment 3. However, the frequency and severity vary substantially:

Sexual Dysfunction

  • Lowest rates: Bupropion, agomelatine, mirtazapine 1, 3
  • Highest rates: Paroxetine > other SSRIs 1, 3

Weight Gain

  • Highest risk: Mirtazapine, TCAs 3, 4
  • Lowest risk: Bupropion, fluoxetine 3

Gastrointestinal Effects

  • Highest rates: SNRIs (duloxetine, venlafaxine) - nausea/vomiting most common reason for discontinuation 1
  • Lower rates: Most SSRIs after initial titration 4

Critical Clinical Considerations

The number needed to harm data is particularly revealing: TCAs require treating only 4-30 patients before one discontinues due to adverse effects, compared to 20-90 patients for SSRIs 1. This 5-fold difference in tolerability is clinically significant for long-term maintenance therapy.

About 63% of patients on second-generation antidepressants experience at least one adverse effect during treatment 1, but the severity and persistence of these effects determine long-term adherence.

Special Population Adjustments

For older adults, the preferred ranking shifts slightly 1:

  • Best choices: Citalopram, escitalopram, sertraline, mirtazapine, venlafaxine, bupropion
  • Avoid: Paroxetine (anticholinergic effects), fluoxetine (agitation risk)

For patients with comorbid physical conditions, sertraline and paroxetine demonstrated efficacy across the most disease subgroups, though tolerability concerns remain 5.

Common Pitfalls to Avoid

  1. Do not use TCAs as first-line agents for long-term treatment unless SSRIs have failed - their poor tolerability profile (NNH 4-30) makes them unsuitable for maintenance therapy 1

  2. Avoid SNRIs (duloxetine, venlafaxine) as first-line choices when long-term tolerability is the priority - they have 40-67% higher discontinuation rates than SSRIs 1

  3. Do not overlook sexual dysfunction - it affects long-term adherence significantly and varies dramatically between agents 3, 4

  4. Monitor weight gain proactively with mirtazapine and TCAs - this late-onset side effect often emerges after initial tolerability assessment 3

References

3
Research

Tolerability issues during long-term treatment with antidepressants.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2004

4
Research

Tolerability of modern antidepressants.

The Journal of clinical psychiatry, 2008

Related Questions

A 68-year-old white male, 21 days post total hip arthroplasty, has itching at the clean, dry surgical site without drainage; what measures can be taken to resolve or minimize the itching?
In a 79-year-old patient receiving enteral tube feeding who presents with diarrhea, which stool test should be ordered first?
In a 55‑year‑old man with a recent electrocardiogram showing sinus rhythm, a QS complex in V1, poor R‑wave progression in V2, left‑atrial enlargement, and a prolonged QT interval, what is the most likely diagnosis and appropriate treatment?
How do I convert an infusion rate of 60 cc per hour to drops per minute using a microdrip set?
What is the appropriate evaluation and management for an 82‑year‑old male presenting with lower abdominal pain and a burning sensation on urination?
Can quetiapine (Seroquel), buspirone (BuSpar), olanzapine, citalopram, or sertraline (Zoloft) cause an increase in blood ammonia levels?
What is the appropriate dosage of vitamin D3 (cholecalciferol) drops for a 6-year-old child?
What are the contraindications to folic acid (folate) supplementation?
How should a radial head fracture with probable intra‑articular extension be managed in a 10‑year‑old child?
What are the indications, dosing regimens, contraindications, monitoring requirements, and alternative therapies for tocilizumab?
What are the DSM‑5 criteria for postpartum depression and is sertraline (Zoloft) safe for a breastfeeding mother?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.